Claims
- 1. A method for the detection of a pathological pregnancy in a pregnant female which comprises the steps of:
- a) contacting a sample of the amniotic fluid or the serum, from the pregnant female with an immobilized first antibody capable of binding to ICAM-1, the first immobilized antibody being insoluble in the sample, to form a first insoluble complex of cICAM-1 and the immobilized first antibody;
- b) contacting the first insoluble complex with a soluble labelled second antibody capable of binding to ICAM-1, to form a final insoluble complex of the labelled second antibody, cICAM-1 and the immobilized first antibody;
- c) separating the final insoluble complex from the sample and any unreacted soluble labelled second antibody;
- d) determining either the amount of label associated with the final insoluble complex or the amount of unreacted label, as a measure of the amount of cICAM-1 in the sample; and
- e) comparing the amount of cICAM-1 in the sample with standards of cICAM-1 normal for amniotic fluid or serum for the stage of pregnancy of the pregnant female and with higher than normal levels of cICAM-1 indicating a risk of an abnormal delivery.
- 2. A method for the detection of a pathological pregnancy in a pregnant female which comprises measuring the amount of cICAM-1 is a sample of the amniotic fluid or the serum from the pregnant female, and then comparing the amount of cICAM-1 in the sample to standards of cICAM-1 normal for amniotic fluid or serum for the stage of pregnancy of the pregnant female and with higher than normal levels of cICAM-1 indicating a risk of an abnormal delivery.
- 3. A method for the detection of a pathological pregnancy in a pregnant female which comprises the steps of:
- a) contacting a sample of the amniotic fluid or the serum of the pregnant female, with a first antibody capable of binding to ICAM-1 and labelled second antibody cable of binding to ICAM-1;
- b) determining the amount of bound labelled second antibody as a measure of the amount of cICAM-1 in the sample; and
- c) comparing the amount of cICAM-1 in the sample with standards of cICAM-1 normal for amniotic fluid or serum for the stage of pregnancy of the pregnant female for the stage of pregnancy of the pregnant female and with higher than normal levels of cICAM-1 indicating a risk of an abnormal delivery.
- 4. A method as recited in claim 3 wherein the first antibody and the labelled second antibody are monoclonal antibodies.
- 5. A method as recited in claim 4 wherein the first antibody is immobilized and the labelled second antibody is soluble.
- 6. A method as recited in claim 5 wherein the immobilized first antibody is immobilized on a solid support.
Parent Case Info
This is a division of application Ser. No. 695,173, filed May 3, 1991, now U.S. Pat. No. 5,223,396.
Non-Patent Literature Citations (1)
Entry |
Chem. Abst. Gen. Subj.-12th Collective Index vol. 106-115 (1987-1991) pp. 17480GS-17482GS. |
Divisions (1)
|
Number |
Date |
Country |
Parent |
695173 |
May 1991 |
|